Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in recurrent venous thromboembolism compared with standard therapy (low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).
1 finding from 1 review
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether idraparinux changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux showed no clear difference in recurrent venous thromboembolism compared with idraparinux (low certainty).
1 finding from 1 review
Major bleeding during the initial treatment ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux may leads to lower major bleeding compared with idraparinux (low certainty).
1 finding from 1 review
Lack of symptom control · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher lack of symptom control compared with continued use (low certainty).
1 finding from 1 review
Pill use (pills/week) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
1 finding from 1 review
Use of healthcare resources (cost effectiveness, time taken to fit, number of dental visits) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).
1 finding from 1 review
Participant satisfaction · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
It is very uncertain whether on‐demand deprescribing changes participant satisfaction compared with continued use (very low certainty).
1 finding from 1 review
Lack of symptom control · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes lack of symptom control compared with continued use (very low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found